支链DNA技术检测人乳头瘤病毒外显子6/7 mRNA在宫颈癌筛查中的应用  

Applying branched-DNA technology testing high-risk human papillomavirus E6/E7 mRNA in liquid-based cytology for cervical cancer screening

作　　者：谢榕[1] 郑雄伟[2] 陈刚[2] 刘桐宇[1] 何诚[2] 林玉珍[1] 杨琳[1] 李桑[1] Lulu ZHANG 

机构地区：[1]福建医科大学教学医院福建省肿瘤医院妇科,福州350014 [2]福建医科大学教学医院福建省肿瘤医院病理科,福州350014 [3]美国弗罗里达大学山德斯肿瘤中心

出　　处：《中国临床药理学杂志》2014年第11期1000-1001,1005,共3页The Chinese Journal of Clinical Pharmacology

基　　金：福建省卫生厅青年基金课题资助项目(2009229)

摘　　要：目的评价支链DNA(b DNA)技术检测高危人乳头瘤病毒外显子6/7(HPV E6/E7)mRNA对宫颈癌筛查的意义。方法用b DNA技术在335例液基细胞学标本(经活检确认病理92例)检测HPV E6/E7 mRNA,其中93例同时检测E6/E7 DNA;对mRNA在不同病理级别分布情况进行分析。结果随着宫颈病变程度加重,HPV E6/E7 mRNA表达率相应增加。E6/E7 DNA与RNA间受试者工作特征曲线(ROC)分析,预测CIN2+病变的最佳工作点为530.53copies·m L-1,ROC曲线下面积为0.789。结论 b DNA技术检测在液基细胞学标本中可很好地检测HPV E6/E7 mRNA。高危HPV E6/E7 mRNA检测的良好阳性似然比可用于宫颈癌筛查,其拷贝值可作为预测宫颈病变的指标。Objective To investigate the role of testing E6/E7 mRNA of high risk human papilloma virus （ HPV） for cervical cancer screening by branched DNA（bDNA）technology.Methods Branched DNA（bD-NA） technology was used to detect high-risk HPV E6/E7 mRNA and DNA directly from 335 liquid cytologic test（LCT） samples（91 samples were recognized by histopathology）.Both of mRNA and DNA were detec-ted in 93 samples.The data according to cytological grades or pathology were statistically analyzed.Results The expression level of HPV E6/E7 mRNA transcripts elevated corresponding to the degree of cervical dyspla-sia.Receiver operating characteristic（ ROC） curve was analyzed for pre-dicting CIN2 ＋, the optimal operating point value was 530.53 copies· mL^-1.Conclusion bDNA technology can be used to detect HPV E6/E7 mRNA well in LCT samples.HPV E6/E7 mRNA test could be a useful tool for cervical cancer screening for its positive likelihood ratio.The copies of mRNA may be used to pool out high-risk patient in cervical cancer screening.

关 键 词：人乳头瘤病毒 支链DNA信号扩增技术 细胞学 E6/E7信使RNA 

分 类 号：R737.33[医药卫生—肿瘤]